ID22939A - Formulasi-formulasi farmasi yang mengandung vorikonozal - Google Patents

Formulasi-formulasi farmasi yang mengandung vorikonozal

Info

Publication number
ID22939A
ID22939A IDW991429A ID991429A ID22939A ID 22939 A ID22939 A ID 22939A ID W991429 A IDW991429 A ID W991429A ID 991429 A ID991429 A ID 991429A ID 22939 A ID22939 A ID 22939A
Authority
ID
Indonesia
Prior art keywords
voriconozal
pharmacy
formulations
pharmacy formulations
voriconozal pharmacy
Prior art date
Application number
IDW991429A
Other languages
English (en)
Indonesian (id)
Inventor
Valerie Denise Harding
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID22939(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ID22939A publication Critical patent/ID22939A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW991429A 1997-06-21 1998-06-02 Formulasi-formulasi farmasi yang mengandung vorikonozal ID22939A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ID22939A true ID22939A (id) 1999-12-16

Family

ID=10814734

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991429A ID22939A (id) 1997-06-21 1998-06-02 Formulasi-formulasi farmasi yang mengandung vorikonozal

Country Status (48)

Country Link
US (1) US6632803B1 (ja)
EP (1) EP1001813B8 (ja)
JP (2) JP2000513029A (ja)
KR (1) KR100372988B1 (ja)
CN (1) CN1125653C (ja)
AP (1) AP912A (ja)
AR (1) AR015900A1 (ja)
AT (1) ATE238812T1 (ja)
AU (1) AU724799B2 (ja)
BG (1) BG64584B1 (ja)
BR (1) BRPI9809468B8 (ja)
CA (1) CA2295035C (ja)
CO (1) CO4940450A1 (ja)
CZ (1) CZ289570B6 (ja)
DE (1) DE69814091T2 (ja)
DK (1) DK1001813T3 (ja)
DZ (1) DZ2523A1 (ja)
EA (1) EA001924B1 (ja)
EG (1) EG23910A (ja)
ES (1) ES2195355T3 (ja)
GB (1) GB9713149D0 (ja)
HK (1) HK1027966A1 (ja)
HR (1) HRP980341B1 (ja)
HU (1) HU228338B1 (ja)
ID (1) ID22939A (ja)
IL (1) IL132918A (ja)
IS (1) IS2004B (ja)
MA (1) MA26508A1 (ja)
ME (1) ME00907B (ja)
MY (1) MY118151A (ja)
NO (1) NO313125B1 (ja)
NZ (1) NZ501066A (ja)
OA (1) OA11232A (ja)
PA (1) PA8453201A1 (ja)
PE (1) PE84899A1 (ja)
PL (1) PL191295B1 (ja)
PT (1) PT1001813E (ja)
RS (1) RS49633B (ja)
SA (1) SA98190159B1 (ja)
SI (1) SI1001813T1 (ja)
SK (1) SK282946B6 (ja)
TN (1) TNSN98090A1 (ja)
TR (1) TR199903191T2 (ja)
TW (1) TW406023B (ja)
UA (1) UA57083C2 (ja)
UY (1) UY25055A1 (ja)
WO (1) WO1998058677A1 (ja)
ZA (1) ZA985364B (ja)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
WO2004017897A2 (en) 2002-08-20 2004-03-04 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
EP1691801A4 (en) * 2003-12-08 2009-12-09 Univ Arizona State SYNERGISTIC ANTICANCER COMPOSITIONS
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达（北京）医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода
EP2018866A1 (en) * 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
WO2009137611A2 (en) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Treatment of pulmonary fungal infection with voriconazole via inhalation
EP2303265B1 (en) * 2008-06-06 2014-12-10 Glenmark Pharmaceuticals Limited Stable topical formulation comprising voriconazole
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药系统
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
EA201270283A1 (ru) 2009-08-19 2012-12-28 Рациофарм Гмбх Способ получения соэвапоратов и комплексы, содержащие вориконазол и циклодекстрин
WO2011064558A2 (en) 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
EP2588116A4 (en) 2010-06-29 2013-12-04 Merck Sharp & Dohme FORMULATIONS OF AN INTRAVENOUS SOLUTION OF POSACONAZOLE STABILIZED BY SUBSTITUTED BETA CYCLODEXTRIN
EP2409699B1 (en) 2010-07-23 2014-04-30 Combino Pharm, S.L. Stable compositions of voriconazole
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
KR101731155B1 (ko) 2011-06-15 2017-04-27 신톤 비.브이. 안정화된 보리코나졸 조성물
EP2561863A1 (en) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Pharmaceutical compositions comprising voriconazole
WO2013103924A2 (en) * 2012-01-05 2013-07-11 Guilford Frederick Timothy Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
KR20200130748A (ko) 2012-05-08 2020-11-19 오닉스 세라퓨틱스, 인크. 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법
AU2013257830A1 (en) 2012-05-11 2014-11-20 Cipla Limited Pharmaceutical composition
US20150352112A1 (en) 2013-01-11 2015-12-10 Xellia Pharmaceuticals Aps Voriconazole inclusion complexes
CA2904670A1 (en) 2013-03-14 2014-09-13 Fresenius Kabi Usa, Llc Voriconazole formulations
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术（石家庄）有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
CN110022857A (zh) 2016-11-18 2019-07-16 艾库里斯抗感染治疗有限公司 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
EP3584245A4 (en) * 2017-02-17 2020-08-26 Wuhan LL Science And Technology Development Co., Ltd. TRIAZOLE ANTIBACTERIAL DERIVATIVE, ASSOCIATED PHARMACEUTICAL COMPOSITION AND USE
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
HUP0003323A3 (en) 2002-01-28
EP1001813B1 (en) 2003-05-02
BR9809468A (pt) 2000-06-20
UY25055A1 (es) 2000-12-29
YU68199A (sh) 2002-06-19
CO4940450A1 (es) 2000-07-24
SI1001813T1 (en) 2004-02-29
US6632803B1 (en) 2003-10-14
EA199900937A1 (ru) 2000-08-28
AR015900A1 (es) 2001-05-30
CZ289570B6 (cs) 2002-02-13
DZ2523A1 (fr) 2003-02-01
BG103882A (en) 2000-07-31
PE84899A1 (es) 1999-09-17
EA001924B1 (ru) 2001-10-22
IS5248A (is) 1999-11-15
HRP980341A2 (en) 1999-02-28
TW406023B (en) 2000-09-21
WO1998058677A1 (en) 1998-12-30
NO313125B1 (no) 2002-08-19
PT1001813E (pt) 2003-07-31
NO995565L (no) 1999-11-30
JP2002332234A (ja) 2002-11-22
ES2195355T3 (es) 2003-12-01
DE69814091T2 (de) 2004-01-22
CN1261287A (zh) 2000-07-26
HK1027966A1 (en) 2001-02-02
PA8453201A1 (es) 2000-05-24
CA2295035A1 (en) 1998-12-30
JP5089004B2 (ja) 2012-12-05
EG23910A (en) 2007-12-30
AU724799B2 (en) 2000-09-28
SK159399A3 (en) 2000-06-12
JP2000513029A (ja) 2000-10-03
AU8110498A (en) 1999-01-04
HRP980341B1 (en) 2001-12-31
BG64584B1 (bg) 2005-08-31
SA98190159B1 (ar) 2005-12-21
EP1001813B8 (en) 2014-02-12
PL191295B1 (pl) 2006-04-28
CN1125653C (zh) 2003-10-29
PL337692A1 (en) 2000-08-28
ME00907B (me) 2007-08-03
BRPI9809468B8 (pt) 2022-01-18
DE69814091D1 (de) 2003-06-05
OA11232A (en) 2003-05-26
DK1001813T3 (da) 2003-07-28
IL132918A0 (en) 2001-03-19
MA26508A1 (fr) 2004-12-20
GB9713149D0 (en) 1997-08-27
IL132918A (en) 2001-09-13
NZ501066A (en) 2001-01-26
UA57083C2 (uk) 2003-06-16
IS2004B (is) 2005-04-15
EP1001813A1 (en) 2000-05-24
CZ409699A3 (cs) 2000-02-16
ATE238812T1 (de) 2003-05-15
KR20010014006A (ko) 2001-02-26
AP912A (en) 2001-12-08
CA2295035C (en) 2005-04-19
BR9809468B1 (pt) 2013-11-12
NO995565D0 (no) 1999-11-12
HU228338B1 (en) 2013-03-28
ZA985364B (en) 1999-12-20
TNSN98090A1 (fr) 2005-03-15
AP9801268A0 (en) 1998-06-30
TR199903191T2 (xx) 2000-09-21
KR100372988B1 (ko) 2003-02-25
SK282946B6 (sk) 2003-01-09
HUP0003323A2 (hu) 2001-06-28
MY118151A (en) 2004-09-30
RS49633B (sr) 2007-08-03

Similar Documents

Publication Publication Date Title
ID22939A (id) Formulasi-formulasi farmasi yang mengandung vorikonozal
MA24473A1 (fr) Formulations
ID28110A (id) Surfaktan alkilbenzenasulfonat yang disempurnakan
NO20001631L (no) 2-metyl-tieno-benzodiazepin formulering
ID26334A (id) Morfolinol yang aktif secara farmasi
ID24654A (id) Formulasi farmasi omeprazola
DK0853945T3 (da) Flydende gonadotropinholdige formuleringer
ID26330A (id) Polipeptida-polipeptida yang bergantung vitamin k yang dimodifikasi
ID23299A (id) Formulasi-formulasi farmasi
IS5425A (is) Læknislyf
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240L (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
PT1130966E (pt) Formulacoes antiparasitarias
TR199800631A3 (tr) Ecza formülasyonu.
NO993096D0 (no) Orale cyklosporinformuleringer
NO980546D0 (no) Farmasöytiske midler
ID26317A (id) Formulasi pelepasan yang diperpanjang
DE69935609D1 (de) Formulierungen enthaltend cefuroxim-axetil
ITMI951395A0 (it) Formulazioni di f-silicone
ITTV970086A0 (it) Struttura di pattino
ID16781A (id) Formulasi-formulasi farmasi
EE9900440A (et) Farmatseutilised kompositsioonid